{"preliminary_commentary":{"by_channel":{"x_thread":2,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT05142696","nct_id":"NCT05142696","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct05142696. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Dose Level 1 (DL1): \\[177Lu\\]Lu-DOTA-TATE 100 mCi with carboplatin AUC 5 D1, etoposide 100 mg/m2 D1-3, and atezolizumab 1200 mg in induction period, then \\[177Lu\\]Lu-DOTA-TATE 100 mCi plus atezolizumab 1200 mg in the maintenance period.","label":"Dose Level 1 (DL1)","type":"EXPERIMENTAL"},{"description":"Dose Level 2a (DL2a): \\[177Lu\\]Lu-DOTA-TATE 150 mCi with carboplatin AUC 5 D1, etoposide 100 mg/m2 D1-3 and atezolizumab 1200 mg in induction period, then \\[177Lu\\]Lu-DOTA-TATE 150 mCi plus atezolizumab 1200 mg in the maintenance period.","label":"Dose Level 2a (DL2a)","type":"EXPERIMENTAL"},{"description":"Dose Level 2b (DL2b): \\[177Lu\\]Lu-DOTA-TATE 150 mCi with carboplatin AUC 5 D1, etoposide 100 mg/m2 D1-3 and atezolizumad 1200 mg in induction period, then \\[177Lu\\]Lu-DOTA-TATE 200 mCi plus atezolizumab 1200 in the maintenance period.","label":"Dose Level 2b (DL2b)","type":"EXPERIMENTAL"},{"description":"Dose Level 3a (DL3a): \\[177Lu\\]Lu-DOTA-TATE 200 mCi with carboplatin AUC 5 D1, etoposide 100 mg/m2 D1-3, and atezolizumab 1200 mg in induction period, then \\[177Lu\\]Lu-DOTA-TATE 200 mCi plus atezolizumab 1200 mg in the maintenance period.","label":"Dose Level 3a (DL3a)","type":"EXPERIMENTAL"},{"description":"Dose Level 3b (DL3b): \\[177Lu\\]Lu-DOTA-TATE 200 mCi with carboplatin AUC 5 D1, etoposide 100 mg/m2 D1-3, and atezolizumab 1200 mg in induction period, then \\[177Lu\\]Lu-DOTA-TATE 250 mCi plus atezolizumab 1200 mg in the maintenance period.","label":"Dose Level 3b (DL3b)","type":"EXPERIMENTAL"},{"description":"Dose Level 4 (DL4): \\[177Lu\\]Lu-DOTA-TATE 250 mCi with carboplatin AUC 5 D1, etoposide 100 mg/m2 D1-3 and atezolizumab 1200 mg in induction period, then \\[177Lu\\]Lu-DOTA-TATE 250 mCi plus atezolizumab 1200 mg in the maintenance period.","label":"Dose Level 4 (DL4)","type":"EXPERIMENTAL"},{"description":"\\[177Lu\\]Lu-DOTA-TATE at recommended dose declared in phase I part in combination with carboplatin, etoposide and atezolizumab (experimental arm)","label":"Phase II Experimental arm","type":"EXPERIMENTAL"},{"description":"Carboplatin, etoposide and atezolizumab alone (control arm)","label":"Phase II Control arm","type":"OTHER"}],"collaborators":[],"completion_date":{"date":"2028-03-07","type":"ESTIMATED"},"conditions":["Extensive Stage Small Cell Lung Cancer"],"enrollment":{"count":55,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"[177Lu]Lu-DOTA-TATE","otherNames":["Lutathera","Lutetium (177Lu) oxodotreotide","Lutetium Lu 177 dotatate"],"type":"DRUG"},{"name":"Atezolizumab","otherNames":[],"type":"DRUG"},{"name":"[68Ga]Ga-DOTA-TATE","otherNames":[],"type":"DRUG"},{"name":"Carboplatin","otherNames":[],"type":"OTHER"},{"name":"Etoposide","otherNames":[],"type":"OTHER"}],"last_update":"2026-08-19","lead_sponsor":"Novartis Pharmaceuticals","official_title":"A Phase Ib/II Dose Finding Study Assessing Safety and Efficacy of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Extensive Stage Small Cell Lung Cancer (ES-SCLC) in Combination With Carboplatin, Etoposide, and Atezolizumab in Induction and With Atezolizumab in Maintenance Phase","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2028-03-07","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Phase 1b: Frequency of dose limiting toxicities (DLTs), Adverse Events (AEs), Serious Adverse Events (SAEs) and AEs leading to treatment discontinuation","timeFrame":"Within the first six weeks of [177Lu]Lu-DOTA-TATE treatment]"},{"measure":"Phase ll: Overall survival (OS)","timeFrame":"In the phase II part: From date of randomization until date of death from any cause, assessed up to 3 years (estimated final Overall Survival (OS) analysis)"}],"references":[],"start_date":{"date":"2022-07-13","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab","url":"https://clinicaltrials.gov/study/NCT05142696"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct05142696"}